The COVID-19 pandemic is rapidly spreading across the world and including countries affected by other infectious disease epidemics, such as HIV, tuberculosis (TB) and malaria. Over the past three decades, the global HIV response has gained experience in developing effective prevention approaches. Th...is brief seeks to provide a summary for decision makers and health programme implementers in low- and middle-income countries (LMICs) to help them make the best possible choices in preventing the virus responsible for COVID-19.
more
COVID-19: Travel, Points of Entry and Border Health
Risk communication encompasses all the basics of health communication but differs in the need for speed and reliance on trust. At times of crisis, leaders are called on to provide a quick, sensitive and trustworthy response.
Children in refugee situations face many potential dangers, such as violence, abuse, exploitation, discrimination, separation from their families, trafficking and military recruitment. The impact of these experiences can be devastating and long-lasting. Children have different needs from adults and ...these needs can only be identified and met if they are approached in a way that is specific to children.
The impact of the COVID-19 global pandemic has exacerbated the dangers faced by children in refugee situations and laid bare the need for their protection and for ensuring that all their human rights are upheld all the time.
The goal of this publication is to share examples of approaches by members of the Initiative that have proven effective for children.
more
Livre I : Dispositions générales
Livre II : Protection générale et promotion de la santé publique
Livre III : Professions de santé et leur régime juridique
Livre IV : Produits pharmaceutiques, autres produits et pharmacopée traditionnelle
Livre V : Dispositions finales
5 Nov. 2020
The policy brief provides a concise summary of information and considerations to ensure optimal management of influenza during the COVID-19 pandemic. It includes a list of technical guidance and other resources to assist policy makers with monitoring the situation, preventing seasonal i...nfluenza, reducing severe complications and mortality, protecting specific populations and communicating to and engaging with the public.
more
This handbook is an adaptation from the WHO Clinical Handbook Health care for women subjected to intimate partner violence or sexual violence developed by the World Health Organization (WHO), UN Women and United Nations Population Fund. The handbook draws on the work from professionals who are dedic...ated to preventing and responding to Gender Based Violence.
The Handbook guides health care service providers to provide comprehensive services to survivors of intimate partner violence and/or sexual violence. It also guides health professionals with respect to relevant stakeholders for referral purposes. The purpose is to ensure that relevant authorities are informed timeously in order act and ensure that those affected by violence receive speedy service as required.
more
In 2016, the risk of premature mortality1 from noncommunicable diseases (NCDs) in Ethiopia was 18.3%. The economic costs of NCDs are significant and are due principally to their impact on the non-health sector (reduced workforce and productivity). In this study, it is estimated that NCDs cost Ethiop...ia at least 31.3 billion birr (US$ 1.1 billion) per year, equivalent to 1.8% of the gross domestic product (GDP). Less than 15% of the costs are for health care.
more
Focusing on preventing and mitigating COVID-19 related risks, the standards aim to protect the health and safety of personnel, while ensuring that organizations continue to deliver on their mandates. Attention is paid to non-discrimination and ensuring that all personnel, regardless of nationality o...r contractual type is equally covered and protected by the minimum standards in the COVID-19 context. It is acknowledged that the implementation of such standards may entail additional costs for organizations, for which a dialogue with donors may be warranted.
more
The well-being of children in sub-Saharan Africa is under siege from all directions since the advent of the COVID-19 pandemic. The region is now suffering its first-ever economic recession, pushing about 50 million people into extreme poverty, a majority of whom are children.
August 2020, The Africa Joint Continental Strategy for COVID-19 is underpinned by the need to limit transmission, prevent deaths and reduce associated harms. Participation by African nations in clinical trials is an essential step to ensure that sufficient data is generated on the safety and efficac...y of the most promising vaccine candidates among the region’s populations.
While current COVID-19 clinical trial activity on the continent is limited, Africa has substantial experience and capabilities to conduct clinical trials for preventative vaccines across a range of diseases, and many organizations on the continent are working tirelessly to help prepare additional trials on potential COVID-19 vaccines. As the number of candidate vaccines in the development pipeline continues to increase, it will be important for organizations responsible for managing clinical trials in the region to partner with vaccine developers to identify potential and appropriate trial locations, provide support to remove any critical obstacles impeding commencement and progress of trials, and to provide oversight ensuring that trials are conducted safely and ethically.
more
Noncommunicable diseases (NCDs) such as cancer, cardiovascular disease, diabetes and chronic respiratory diseases and their risk factors are an increasing public health and development challenge in Kazakhstan. This report provides evidence through three analyses that NCDs reduce economic output and ...discusses potential options in response, outlining details of their relative returns on investment. An economic burden analysis shows that economic losses from NCDs (direct and indirect costs) comprise 2.3 trillion tenge, equivalent to 4.5% of gross domestic product in 2017. An intervention costing analysis provides an estimate of the funding required to implement a set of policy interventions for prevention and clinical interventions. A cost–benefit analysis compares these implementation costs with the estimated health gains and identifies which policy packages would give the greatest returns on investment. For example, the salt policy package achieved a benefit-to-cost ratio of 118.4 over 15 years, a return of more than 118 tenge for every 1 tenge invested.
more
Interim Guidance, published 11 January 2021.
The cold chain is necessary to prevent damage to vaccines caused by heat exposure. However, improper use of cold chain equipment may cause damage to freeze-sensitive vaccines (i.e. those vaccines containing alum adjuvant or oil-emulsion adjuvant). Studie...s conducted in several countries with hot and cold climates show frequent occurrences of sub-zero temperatures in the cold chain. The most common cause of exposure to freezing temperature is the failure to correctly condition ice packs prior to transport. Vaccines that are inadvertently frozen lose potency, increase wastage rates and increase the risk of adverse events following immunization (AEFI). Vaccine carriers protect vaccine potency during immunization sessions and transport to outreach sites. This guidance document is intended to help inform which type of vaccine carrier to select based on local context, to maintain vaccine quality, especially at service delivery points.
more
18 Janaury 2021
EU/EEA Member States and the UK have increased their laboratory capacity tremendously over the past 11 months as the majority of the Member States reported sufficient testing capacity until March 2021.
Many countries are adding rapid antigen detection tests (RADT) to their ...testing strategies in order to reduce pressure on RT-PCR testing.
Some Member States have already included RADT in their case definition.
The main bottlenecks, such as shortages of laboratory consumables and human resources, as well as sample storing facilities, continue to exist and may affect the overall laboratory response to COVID-19.
more